NAMI-A

Modify Date: 2024-01-03 12:06:53

NAMI-A structure	Common Name	NAMI-A
	CAS Number	201653-76-1	Molecular Weight	458.18
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₅H₁₀Cl₄N₂ORuS _. C₃H₄N₂ _. H	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of NAMI-A

NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.In vitro: NAMI-A can significantly affect tumor cells with metastatic ability.The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations. [1] The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397. [2]In vivo: The reference for NAMI-A is 35 mg/kg/day. [1]

Name	NAMI-A

Description	NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.In vitro: NAMI-A can significantly affect tumor cells with metastatic ability.The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations. [1] The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397. [2]In vivo: The reference for NAMI-A is 35 mg/kg/day. [1]
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FAK Research Areas >> Cancer
References	[1]. Sava G et al. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res. 2003 May;9(5):1898-905. [2]. Pelillo C et al. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A. J Inorg Biochem. 2016 Jul;160:225-35.

Description

Related Catalog

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FAK

Research Areas >> Cancer

References

[1]. Sava G et al. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res. 2003 May;9(5):1898-905.

[2]. Pelillo C et al. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A. J Inorg Biochem. 2016 Jul;160:225-35.